One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...

Editorial: Polling shows that the public supports this new technology, but the conversation must move beyond simple questions of safety ...

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

The Gene Editing Therapeutics market, driven by advancements in CRISPR technology and precision medicine, presents opportunities in oncology, rare genetic disorders, and chronic diseases. Investment ...

CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...

Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...

An extremely precise genome editing technique called base editing has been used for the first time by Cambridge scientists to ...

People living with hereditary angioedema, a rare genetic condition that triggers sudden, painful swelling of the face, throat ...

Developing novel ways to refine, reduce and replace the use of animals in research and enhance animal and human health.